Natalya Goncalves Pereira

Natalya Goncalves Pereira

Auto-generated profile, based on publicly available information

Natalya Goncalves Pereira

Department of Obstetrics and Neonatology Hospital e Maternidade Sepaco São Paulo Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
Emeline MaisonneuveEmeline Maisonneuve
Emeline Maisonneuve
OBOdette De Bruin
Odette De Bruin
GFGuillaume FAVRE
Guillaume FAVRE
EOErin Oakley
Erin Oakley
JKJenny Yeon Hee Kim
Jenny Yeon Hee Kim
MSMiriam C. J. M. Sturkenboom
Miriam C. J. M. Sturkenboom

1 January 2024 in Journal of Pregnancy
Verified
Journal Article
Open access
PDF file
RRRicardo Rohweder
Ricardo Rohweder
NPNatálya G. Pereira
Natálya G. Pereira
Bruna Hipólito MichelettiBruna Hipólito Micheletti
Bruna Hipólito Micheletti
JMJéssica Mosello
Jéssica Mosello
JCJúlia R. M. Campos
Júlia R. M. Campos
LSLavinia Schuler-Faccini
Lavinia Schuler-Faccini
There is limited evidence about the use of medications among pregnant women with COVID‐19, as well as risk factors for hospitalization due to COVID‐19 in pregnancy. We aimed to describe the use of medications among SARS‐CoV‐2‐positive pregnant women at the time around infection and identify predictors for hospitalization due to COVID‐19 in two hospitals in Brazil. This is a hospital record‐based study among pregnant women with positive SARS‐CoV‐2 tests between March 2020 and August 2022 from two Brazilian hospitals. Characteristics of sociodemographic, obstetrical, and COVID‐19 symptoms were extracted retrospectively. The prevalence use of medications was based on self‐reported use, and this was administered at the hospital. Logistic regression was used to estimate predictors of hospitalization due to COVID‐19. There were 278 pregnant women included in the study, of which 41 (14.7%) required hospitalization due to COVID‐19. The remaining 237 (85.3%) had mild symptoms or were asymptomatic. Most of the women had the infection in the third trimester (n = 149; 53.6%). The most prevalent medications used across all trimesters were analgesics (2.4% to 20.0%), antibacterials (15.0% to 23.1%), and corticosteroids (7.2% to 10.4%). Pre‐ or gestational hypertensive disorder (odds ratio (OR) 4.94, 95% confidence interval (CI) 1.65, 14.87) and having at least one dose of vaccine against SARS‐CoV‐2 (OR 0.13, 95% CI 0.04, 0.39) were associated with hospitalization due to COVID‐19. Analgesics, antibacterials, and corticosteroids were the most frequently used medications among pregnant women with COVID‐19. Women with hypertensive disorders have almost a five‐fold increased risk of hospitalization due to COVID‐19. Vaccination was the strongest protective factor for severe COVID‐19. The COVID‐19 vaccination among pregnant women should be promoted, and pregnant women diagnosed with COVID‐19 who have hypertensive disorders should be closely monitored.